DRMA — Dermata Therapeutics Cashflow Statement
0.000.00%
- $1.20m
- -$3.54m
Annual cashflow statement for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.72 | -3.24 | -7.9 | -9.61 | -7.79 |
Depreciation | |||||
Non-Cash Items | 0.873 | -0.036 | 1.92 | 0.93 | 0.522 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.075 | -0.756 | 0.29 | -0.154 | 0.864 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -3.92 | -4.03 | -5.69 | -8.83 | -6.41 |
Financing Cash Flow Items | -0.012 | 0 | — | — | -0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 4.73 | 2.57 | 16 | 4.28 | 7.61 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.812 | -1.46 | 10.3 | -4.56 | 1.2 |